Global Community

SSE plc — Investment Memo Investment Thesis SSE is a core UK infrastructure compounder positioned to benefit from the energy transition. It combines: Regulated electricity networks → stable, inflation-linked returns Renewables pipeline → long-term growth Dividend yield → immediate income Hybrid profile: defensive base + structural growth Business Model 1.Read more

Q2 FY7/26 results update Prioritizing investment in human capital – Q1-2 FY7/26 results were mixed, with sustained high double-digit sales growth and stable high gross margins, with sustained improvement at the parent company level. However, this was offset by an accelerated recruitment profile, which resulted in negative YoY OP growth.Read more

Here are data based on 3rd quarter: BVPS ~ EUR 171.5 Normalized ROE: 13–16% Payout: 50–60% CET1 above SREP Regarding publish strategy for the 2026 Strategy target: Recurring revenues: EUR 1.1bn → > EUR 2.0bn Profit: EUR 0.5bn → > EUR 1.0bn CIR: 46% → <45% ROE: >15% (including 1–2 p.p. uplift from strategic initiatives) P/B: 0.8x → >1.0x Payout ratio: 40% → 50–60% Capital and risk CET1: 16.4% → >13% Assumptions NIM remains >3.2% (this might be difficult to keep) CIR improves toward 43% (now is cca 45%) Strong growth in fee income ( they plan to proceed with acquisitions) ROE 16–17% ( now is around 15%) Payout 60% Outcome BVPS 2030: ~EUR 250 P/B: 1.15x Share price: ~EUR 285 Cumulative dividends: ~EUR 75 Total value in 2030: ~EUR 360 Scenario is bullish but there is a room to achieve this. A possible future greater presence on the Croatian market, which is burdened with certain problems from the political past of relations between Slovenia and Croatia, would probably catapult the share above €360 by 2030.Read more

The Valuation Model: The Math Behind the $6.65 Target Our valuation is built on a theoretical 2031 "Bull Case" scenario, assuming the successful execution of Commercial Phase 1 and the initiation of Phase 2 at the Fort Cady facility. 2031 Projected Revenue: $550,000,000 USD (Driven by core boric acid production and a ~20% shift into high-margin advanced derivatives like Meta Boric Acid and Ferroboron).Read more

RXRX is a terrible biotech only because the INSIDERS themselves don’t believe in it! All they’re doing is milking the heck out of this doomed stock!Read more

When considering the hypothetical question of what I would buy in the aftermath of another global financial crisis–type event, a few key criteria come to mind. The ideal company should be financially sound, likely to be indiscriminately sold off alongside other financial stocks and well positioned to recover strongly regardless of the future direction of the economic system.Read more

$BLCO & $COO. The Silence After the AGM: A Retail Investor’s Timeline, Findings, and Opinion on an Unprecedented Governance Failure By a Retail Investor and Portfolio Manager (Opinion) --- I.Read more

Fibromat (M) Berhad may not be one of the most talked-about names on Bursa, but from a fundamental perspective, the company is starting to look more interesting than many investors may realise. The group is mainly involved in erosion control solutions , geotechnical-related installation works , and the manufacturing and sale of in-house erosion control products.Read more

Initiating coverage A serial incubator of digital businesses, trading at a material discount – Ceres has a demonstrated track record of building businesses from scratch and crystallizing value at attractive returns. The Company incubated D2C from ¥10mn to ¥4.9bn in revenue, grew labol's GMV approximately 70x in four years, and generated a post-tax MOIC of 6.6x and ~31% IRR on the YUMEMI investment over eight years.Read more